| __timestamp | BioCryst Pharmaceuticals, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 51796000 | 20707000 |
| Thursday, January 1, 2015 | 72758000 | 17831000 |
| Friday, January 1, 2016 | 61008000 | 18047000 |
| Sunday, January 1, 2017 | 66962000 | 11033000 |
| Monday, January 1, 2018 | 84888000 | 13432000 |
| Tuesday, January 1, 2019 | 107068000 | 52072000 |
| Wednesday, January 1, 2020 | 122964000 | 51488000 |
| Friday, January 1, 2021 | 208808000 | 85727000 |
| Saturday, January 1, 2022 | 253297000 | 95518000 |
| Sunday, January 1, 2023 | 216566000 | 125046000 |
Unleashing the power of data
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, BioCryst Pharmaceuticals and Geron Corporation have demonstrated contrasting strategies in their R&D expenditures. From 2014 to 2023, BioCryst Pharmaceuticals consistently outpaced Geron Corporation, with an average annual R&D investment nearly 2.5 times higher. Notably, BioCryst's R&D spending surged by over 400% from 2014 to 2022, peaking in 2022 with a 253% increase compared to 2014. Meanwhile, Geron Corporation's R&D investments, though more modest, showed a steady upward trend, culminating in a 504% increase by 2023. This divergence highlights BioCryst's aggressive pursuit of innovation, while Geron maintains a more measured approach. As the biotech landscape continues to shift, these investment patterns may well dictate the future breakthroughs in medical science.
R&D Insights: How Sanofi and Geron Corporation Allocate Funds
Research and Development: Comparing Key Metrics for Incyte Corporation and Geron Corporation
Who Prioritizes Innovation? R&D Spending Compared for Incyte Corporation and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Sarepta Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Investment: Ascendis Pharma A/S vs BioCryst Pharmaceuticals, Inc.
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for PTC Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs Geron Corporation
Analyzing R&D Budgets: HUTCHMED (China) Limited vs Geron Corporation
Protagonist Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: MannKind Corporation vs BioCryst Pharmaceuticals, Inc.